Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Last trade$0.698
Day change-$0.552 (-44.16%)
Day range$0.581 – $1.26
Volume553,638
Market cap$9M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$8.79M
Price / earnings
—
Price / book
-0.03×
Price / sales
0.28×
EV / sales
2.89×
EV / EBITDA
-0.33×
Profitability
Earnings per share
-$63.73
Return on assets
-176.82%
Return on equity
145.41%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.27×
Current ratio
0.07×
Quick ratio
0.06×
Cash ratio
0×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$17.81M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SCLX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Q3 FY2024 Sep 30, 2024
Revenue
$7.64M
$8.61M
$4.79M
$10.56M
$9.9M
$5M
$14.9M
$14.44M
Cost of revenue
$3.68M
$4.45M
$2.61M
$3.33M
$3.27M
$1.38M
$4.69M
$3.77M
Gross profit
$3.97M
$4.17M
$2.18M
$7.23M
$6.62M
$3.62M
$10.21M
$10.67M
Selling, general and administrative
$27.96M
$31.03M
$30.16M
$188.82M
$19.84M
$28.06M
$35.41M
$29.73M
Research and development
$3.34M
$3.21M
$8.17M
$3.9M
$6.19M
$2.46M
$2.18M
$2.35M
Total operating expenses
$33.39M
$36.34M
$113.27M
$193.74M
$27.13M
$31.52M
$38.59M
$30.59M
Operating income
-$29.42M
-$32.17M
-$111.09M
-$186.51M
-$20.51M
-$27.9M
-$28.38M
-$19.92M
Interest expense
-$6.1M
-$3.78M
-$3.5M
-$2.8M
-$2.68M
-$2.48M
-$285K
-$576K
Income before taxes
-$114.98M
-$45.65M
-$46.1M
-$257.82M
-$44.03M
-$26.08M
-$6.46M
-$4.39M
Income taxes
$7K
$0
$6K
$1K
$19K
$0
-$1K
$0
Net income
-$114.99M
-$45.65M
-$46.11M
-$257.82M
-$44.05M
-$26.08M
-$6.46M
-$4.39M
Net income attributable to common shareholders
-$114.73M
-$43.27M
-$33.11M
-$257.23M
-$86.06M
-$26.08M
-$6.46M
-$4.39M
EBITDA
-$26.58M
-$29.3M
-$35.9M
-$185.49M
-$19.4M
-$26.9M
-$27.37M
-$21.41M
Basic earnings per share
-$16.65
-$6.28
-$3.53
-$22.17
-$7.42
-$2.26
-$0.26
-$0.58
Diluted earnings per share
-$16.65
-$6.28
-$3.53
-$22.17
-$7.42
-$2.26
-$0.26
-$0.58
Recent news
Company coverage with links to the original publishers.
Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million strategic investment at $15 per share (approximately 6.67 million shares). The investment will support Scilex's growth initiatives including product development, commercialization, acquisitions, and strategic partnerships. The deal remains subject to due diligence, definitive agreements, board and stockholder approvals, and regulatory clearances.
Scilex Holding Company shares surged 18.79% after announcing that its Dream Bowl I Meme Coin tokens will begin trading on Biconomy Exchange as early as June 23. The listing is expected to improve liquidity and enable broader distribution for eligible token holders. Scilex is a biotech company focused on non-opioid pain management products.
Scilex Holding Company announced that its board has set June 15, 2026 as the payment date for a dividend of Semnur Pharmaceuticals common stock to Scilex shareholders. The company plans to distribute approximately 14.0 million shares of Semnur (out of 186 million owned) on a 1:1 basis for each Scilex share held as of the June 1, 2026 record date. The dividend is subject to board revocation if there are material changes to solvency or surplus analysis.
Scilex Holding Company's board approved a dividend distribution of Semnur Pharmaceuticals common stock to its shareholders, with a record date of June 1, 2026. Scilex will distribute approximately 10.7 million shares of its ~186 million Semnur holdings to eligible equity holders at a 1:1 ratio. The payment date will be determined by subsequent board resolutions within 60 days of the record date, though the board retains the right to change the record date or revoke the dividend.
Scilex Holding Company announced that its subsidiaries ACEA Therapeutics and ACEA Pharma entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited for $1 billion in newly-issued shares. Upon closing, Phoenix will be renamed ACEA Pharma and listed on Nasdaq, with ACEA Thera retaining approximately 82% ownership. The transaction is expected to close by end of Q2 2026, subject to regulatory and stock exchange approvals.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.